Given the variable penetrance and expressivity of the TTN gene in cardiomyopathy, which is often responsive to guideline-directed medical therapy for heart failure, identification of the point during the disease course when there is clinical equipoise for trials related to gene editing and regulation merits careful scrutiny. The gene discussed is TTN; the disease is cardiomyopathy.